Novo Nordisk plans to discontinue Saxenda in early 2027 as sales decline
MedPage's endocrinology roundup also has petrelintide phase II weight loss of up to 9.2% and over 100,000 new oral Wegovy scripts in two months.
Recap by typeshit. Full story at MedPage Today.